Pebrilzo Advances Biocon’s Biosimilar Oncology Portfolio in Europe

Biocon Biologics has reached an important regulatory milestone for its pertuzumab biosimilar, Pebrilzo®, after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for the medicine. The recommendation covers treatment of HER2-positive breast cancer in adults across multiple disease settings.

The recommendation is particularly notable because Pebrilzo is the first biosimilar medicine recommended for approval under the EMA's tailored clinical approach. This regulatory pathway places greater emphasis on advanced analytical and comparative pharmacokinetic evidence when establishing biosimilarity, where appropriate.

A Targeted Approach to Demonstrating Biosimilarity

Pebrilzo contains pertuzumab, a monoclonal antibody that binds to the HER2 receptor. The medicine is designed to inhibit proliferation of tumour cells that overexpress HER2.

Biocon reports that extensive structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated a high degree of similarity between Pebrilzo and the reference biologic, without clinically meaningful differences in quality, safety or efficacy.

Key Highlights

✦ Pertuzumab biosimilar developed by Biocon Biologics

✦ Brand name: Pebrilzo®

✦ 420 mg concentrate for solution for infusion

✦ Positive EMA CHMP opinion recommending marketing authorisation

✦ First biosimilar medicine recommended under the EMA tailored clinical approach

✦ Based on extensive analytical characterization and comparative pharmacokinetic data

✦ Targets HER2-positive breast cancer

✦ Intended for use in combination with other established therapies in specified patient populations

Potential Clinical Use

Pebrilzo is indicated for use with trastuzumab and chemotherapy in the neoadjuvant treatment of adults with HER2-positive locally advanced, inflammatory or early-stage breast cancer who have a high risk of recurrence. It is also indicated for specified adjuvant treatment of HER2-positive early breast cancer.

For metastatic or locally recurrent unresectable HER2-positive breast cancer, the proposed indication includes use with trastuzumab and docetaxel in adults who have not previously received anti-HER2 therapy or chemotherapy for their metastatic disease.

What Happens Next?

The positive CHMP opinion is a recommendation, not the final European Union marketing authorisation. The European Commission will now conduct its final review and make the formal decision. Until that decision is granted, Pebrilzo is not authorised for use in the European Union.

The development also illustrates the evolving regulatory approach to biosimilars, where highly detailed analytical and pharmacokinetic evidence can play a central role in establishing similarity to an established biologic. The EMA identifies Pebrilzo as the first biosimilar medicine recommended for approval following its tailored clinical approach.

Conclusion

Biocon's Pebrilzo® pertuzumab biosimilar has advanced through the European regulatory process with a positive CHMP recommendation for adults with HER2-positive breast cancer. The milestone combines Biocon Biologics' biosimilar development work with an evolving EMA approach to clinical development and represents another step toward potential European availability, subject to the European Commission's final decision.